Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 7/2019

01-07-2019 | Lymphoma | Original Article

Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison

Authors: Dr. med. Laila König, Dipl.-Inform. Med. Nina Bougatf, Dr. med. Juliane Hörner-Rieber, Naved Chaudhri, Thomas Mielke, Dr. sc. hum. Sebastian Klüter, Dr. med. Matthias Felix Haefner, Prof. Dr. med. Stefan Rieken, Prof. Dr. Thomas Haberer, Prof. Dr. med. Dr. rer. nat. Jürgen Debus, Prof. Dr. med. Klaus Herfarth

Published in: Strahlentherapie und Onkologie | Issue 7/2019

Login to get access

Abstract

Purpose

Current research approaches in lymphoma focus on reduction of therapy-associated long-term side effects. Especially in mediastinal lymphoma, proton beam radiotherapy (PT) may be a promising approach for reducing the dose to organs at risk (OAR).

Patients

In total, 20 patients were irradiated with active scanning PT at Heidelberg Ion Beam Therapy Center (HIT) between September 2014 and February 2017. For comparative analysis, additional photon irradiation plans with helical intensity-modulated radiotherapy (IMRT) were calculated and quantitative and qualitative dose evaluations were made for both treatment modalities. Toxicity and survival outcomes were evaluated.

Results

Clinical target volume coverage was comparable in both treatment modalities and did not significantly differ between IMRT and PT. Nevertheless, PT showed superiority regarding the homogeneity index (HIPT = 1.041 vs. HIIMRT = 1.075, p < 0.001). For all OAR, PT showed significantly higher dose reductions compared with IMRT. In particular, the dose to the heart was reduced in PT (absolute dose reduction of Dmean of 3.3 Gy [all patients] and 4.2 Gy [patients with pericardial involvement]). Likewise, the subgroup analysis of female patients, who were expected to receive higher doses to the breast, showed a higher dose reduction in Dmean of 1.2 Gy (right side) and 2.2 Gy (left side). After a median follow-up of 32 months (range 21–48 months), local and distant progression free survival (LPFS and DPFS) were 95.5% and 95.0%, respectively. Radiotherapy was tolerated well with only mild (grade 1–2) radiation-induced acute and chronic side effects.

Conclusion

A significant reduction in the dose to the surrounding OAR was achieved with PT compared with photon irradiation, without compromising target volume coverage. Dosimetric advantages may have the potential to translate into a reduction of long-term radiation-induced toxicity in young patients with malignant lymphoma of the mediastinum.
Literature
1.
Girinsky T et al (2006) Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64(1):218–226CrossRefPubMed
2.
Goodman KA et al (2005) Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62(1):198–206CrossRefPubMed
3.
Held G et al (2014) Role of radiotherapy to bulky disease in elderly patients with aggressive B‑cell lymphoma. J Clin Oncol 32(11):1112–1118CrossRefPubMed
4.
Ng AK et al (2016) Re-examining the role of radiation therapy for diffuse large B‑cell lymphoma in the modern era. J Clin Oncol 34(13):1443–1447CrossRefPubMed
5.
Pfreundschuh M et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6‑year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013–1022CrossRefPubMed
6.
Engert A et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652CrossRefPubMed
7.
von Tresckow B et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907–913CrossRef
8.
Engert A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799CrossRefPubMed
9.
Illidge T et al (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89(1):49–58CrossRefPubMed
10.
Specht L et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862CrossRefPubMed
11.
Kramer M et al (2000) Treatment planning for heavy-ion radiotherapy: physical beam model and dose optimization. Phys Med Biol 45(11):3299–3317CrossRefPubMed
12.
Kramer M et al (2004) Treatment planning for scanned ion beams. Radiother Oncol 73(Suppl 2):S80–S85CrossRefPubMed
13.
Kramer M, Scholz M (2000) Treatment planning for heavy-ion radiotherapy: calculation and optimization of biologically effective dose. Phys Med Biol 45(11):3319–3330CrossRefPubMed
14.
Voong KR et al (2014) Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 9:94CrossRefPubMedPubMedCentral
15.
Emami B et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122CrossRefPubMed
16.
Haberer T et al (1993) Magnetic scanning system for heavy ion therapy. Nucl Instrum Methods Phys Res A 330(1):296–305CrossRef
17.
18.
Shaw E et al (1993) Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 27(5):1231–1239CrossRefPubMed
19.
Kessel KA et al (2014) Five-year experience with setup and implementation of an integrated database system for clinical documentation and research. Comput Methods Programs Biomed 114(2):206–217CrossRefPubMed
20.
Bougatf N, Bendl R, Debus J (2015) Towards secondary use of heterogeneous radio-oncological data for retrospective clinical trials: service-oriented connection of a central research database with image analysis tools
21.
Cheson BD et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586CrossRefPubMed
22.
Hoppe BS et al (2012) Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys 83(1):260–267CrossRefPubMed
23.
Hoppe BS et al (2012) Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84(2):449–455CrossRefPubMed
24.
Zeng C et al (2016) Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. Acta Oncol 55(9–10):1132–1138CrossRefPubMed
25.
Oeffinger KC et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355(15):1572–1582CrossRefPubMed
26.
Held G et al (2013) Impact of rituximab and radiotherapy on outcome of patients with aggressive B‑cell lymphoma and skeletal involvement. J Clin Oncol 31(32):4115–4122CrossRefPubMed
27.
Borchmann P et al (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29(32):4234–4242CrossRefPubMed
28.
Girinsky T et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88(2):202–210CrossRefPubMed
29.
Holzhauser E et al (2017) Patterns of failure of diffuse large Bcell lymphoma patients after involved-site radiotherapy. Strahlenther Onkol 193(12):1014–1023CrossRefPubMed
30.
Maraldo MV et al (2014) The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 61(4):717–722CrossRefPubMed
31.
Hall EJ (2006) Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65(1):1–7CrossRefPubMed
32.
van Nimwegen FA et al (2016) Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin Lymphoma. J Clin Oncol 34(3):235–243CrossRefPubMed
33.
Lipshultz SE et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128(17):1927–1995CrossRefPubMed
34.
Tukenova M et al (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28(8):1308–1315CrossRefPubMed
35.
van Leeuwen FE, Ng AK (2016) Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program 2016(1):323–330CrossRefPubMedPubMedCentral
36.
37.
Mulrooney DA et al (2016) Cardiac outcomes in adult survivors of childhood cancer exposed to Cardiotoxic therapy: a cross-sectional study. Ann Intern Med 164(2):93–101CrossRefPubMedPubMedCentral
38.
Schaapveld M et al (2015) Second cancer risk up to 40 years after treatment for Hodgkin’s Lymphoma. N Engl J Med 373(26):2499–2511CrossRefPubMed
39.
40.
De Bruin ML et al (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27(26):4239–4246CrossRefPubMed
41.
Jiang HY et al (2005) Simulation of organ-specific patient effective dose due to secondary neutrons in proton radiation treatment. Phys Med Biol 50(18):4337–4353CrossRefPubMed
42.
Andolino DL et al (2011) Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys 81(4):e667–71CrossRefPubMed
43.
Schneider U et al (2002) Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys 53(1):244–251CrossRefPubMed
44.
Schneider U, Lomax A, Lombriser N (2000) Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin’s disease with photon and proton radiation. Radiat Res 154(4):382–388CrossRefPubMed
45.
Chung CS et al (2013) Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 87(1):46–52CrossRefPubMed
46.
Halg RA et al (2014) Measurements of the neutron dose equivalent for various radiation qualities, treatment machines and delivery techniques in radiation therapy. Phys Med Biol 59(10):2457–2468CrossRefPubMed
47.
48.
Gottschalk B (2006) Neutron dose in scattered and scanned proton beams: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;65:1–7). Int J Radiat Oncol Biol Phys 66(5):1594 (author reply 1595)CrossRefPubMed
49.
Richter D et al (2014) Four-dimensional patient dose reconstruction for scanned ion beam therapy of moving liver tumors. Int J Radiat Oncol Biol Phys 89(1):175–181CrossRefPubMed
Metadata
Title
Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison
Authors
Dr. med. Laila König
Dipl.-Inform. Med. Nina Bougatf
Dr. med. Juliane Hörner-Rieber
Naved Chaudhri
Thomas Mielke
Dr. sc. hum. Sebastian Klüter
Dr. med. Matthias Felix Haefner
Prof. Dr. med. Stefan Rieken
Prof. Dr. Thomas Haberer
Prof. Dr. med. Dr. rer. nat. Jürgen Debus
Prof. Dr. med. Klaus Herfarth
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 7/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-019-01460-7

Other articles of this Issue 7/2019

Strahlentherapie und Onkologie 7/2019 Go to the issue

Literatur kommentiert

Vitamin D und Omega-3-Fettsäuren senken das Risiko für Krebs und kardiovaskuläre Ereignisse nicht

Original Article

Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy

Original Article

Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old Asian women with breast cancer

Literatur kommentiert

Radiochirurgie und operative neurovaskuläre Dekompression annähernd gleichwertig bei der Behandlung von Trigeminusneuralgien

Original Article

Long-term cosmetic outcome after preoperative radio-/chemotherapy in locally advanced breast cancer patients

Original Article

Single-center long-term results from the randomized phase-3 TARGIT-A trial comparing intraoperative and whole-breast radiation therapy for early breast cancer